





# The Alberta Opioid Dependency Treatment (ODT) Virtual Training Program

The Alberta ODT Virtual Training Program is a critical component of broader efforts to respond to the opioid crisis in Alberta by improving the capacity of prescribers and allied health care team members involved in treating individuals with opioid use disorder (OUD).

The Alberta ODT Virtual Training Program includes:

-  **Seven (7) interactive eLearning modules**
-  **Ten (10) subject matter expert (SME) interviews**
-  **Five (5) Entrustable Professional Activity (EPA) Simulations**



The Alberta ODT Virtual Training Program aligns with current evidence, regulations and national guidelines, and satisfies the College of Physician & Surgeons of Alberta (CPSA) requirements for initiating and maintaining opioid agonist therapy (OAT).

\*An application for accreditation has been submitted.

For access to the non-accredited modules & resource content, you can log in after September 16, 2018 to [www.ahs.ca/PACES](http://www.ahs.ca/PACES)

For access to the CME accredited modules, please log in after September 16th, 2018 to <http://ecme.ucalgary.ca/>



# The Alberta ODT Virtual Training Program

## ----- Module Guide -----

# 01

### The Opioid Crisis

#### KNOWLEDGE

Describe the national and provincial impact of the current opioid crisis; Describe current action, legislation, and prescribing guidelines that have been established in response to the opioid crisis.

#### SME INTERVIEWS

Explain how Canada's current opioid crisis came to be; Explain the impact of the opioid crisis on individuals, and families.

# 02

### Understanding Opioids

#### KNOWLEDGE

Describe how opioids evolved; Explain the impact opioids have on the brain and body, and the routes of administration; Describe the various opioids available;

#### SME INTERVIEWS

Explain the endogenous/ exogenous system and interaction with opioid receptors. Explain opioid agonist activity and affinity; Describe current trends in opioid use.

# 03

### Impact of Opioid Use

#### KNOWLEDGE

Explain the neurobiology of addiction; Describe Opioid Use Disorder; Discuss the impacts of opioids on mental & physical health; Explore OUD across special populations;

#### SME INTERVIEWS

Discuss the biopsychosocial-spiritual model of addiction; Explain the components of a comprehensive assessment for opioid dependency treatment.

#### EPA-SIMULATION

Conduct a comprehensive assessment for opioid use disorder (OUD).

# 04

### Reducing Harm & Recognizing Opioid Poisoning

#### KNOWLEDGE

Define harm reduction and the philosophy & principles behind it; Describe four primary components of harm reduction; Explain the signs and symptoms of opioid intoxication and poisoning.

#### SME INTERVIEWS

Explain harm reduction approaches as relates to opioid use disorder and current initiatives underway in Alberta.

#### EPA-SIMULATIONS

Assess for an opioid poisoning and respond with administration of Naloxone

# 05

### Treatment Planning: Opioid Agonist Treatment (OAT) Therapy

#### KNOWLEDGE

Define opioid agonist treatment (OAT) therapy and how aligns with the spectrum of treatment intensity; Describe 1st line vs 2nd line treatment recommendations; Explain how to initiate, maintain and convert when prescribing OAT therapies.

#### SME INTERVIEWS

Explain efficacy of medically assisted withdrawal treatment; Describe specialty led OAT therapy (SROM & iOAT); Explain clinical requirements & nuances of OAT monitoring.

#### EPA-SIMULATIONS

Initiate an individual on methadone; initiate an individual on Buprenorphine /naloxone through home induction; Convert an individual from methadone to buprenorphine/naloxone.

# 06

### Treatment Planning: Psychosocial Interventions

#### KNOWLEDGE

Describe integrated treatment; Discuss how motivation for change & comprehensive assessment inform psychosocial intervention & treatment placement; Explain the goals of psychosocial treatment;

#### SME INTERVIEWS

Explain the efficacy of various psychosocial interventions in relation to opioid use disorder

# 07

### Special Populations

#### KNOWLEDGE

Discuss the prevalence of OUD across developmental and special population cohorts; Describe prescribing OAT recommendations & special considerations for each population cohort.

#### SME INTERVIEWS

Explain clinical interactions & strategies most supportive to the unique requirements of demographic and special population cohorts presenting with OUD.

**PLEASE SUBMIT YOUR QUESTIONS AND DE-IDENTIFIED CLIENT SCENARIO INQUIRIES TO [concurrent.disorders@ahs.ca](mailto:concurrent.disorders@ahs.ca).**

**QUESTIONS AND CASE SCENARIOS WILL BE THEMED & DISCUSSED DURING THE MONTHLY COURSE WEBINAR, AND THE MONTHLY ODT VIRTUAL HEALTH LEARNING SESSIONS.**